Disodium pamidronate in the treatment of bone metastases from breast cancer

M. Colleoni, A. M. Bochicchio, F. Nole, E. Bajetta

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aims and Background: Symptomatic relief of bone metastases with biphosphonates has been previously reported, but limited data are available on the possibility of the induction of sclerosis in osteolytic lesions. Methods: We therefore initiated an open study with disodium pamidronate (45 mg infused over 1 h and repeated every 21 days) in patients with bone metastases from breast cancer pretreated with chemotherapy and/or hormone therapy. Fourteen patients with measurable lytic or mixed bone disease entered the study. No other systemic therapy for breast cancer was allowed after their inclusion in the study. Results: No radiologic evidence of bone sclerosis of lytic disease was seen. After 2 months of therapy, 9 patients had progressed and 5 had stable disease. The median time to progression of bone disease was 1.6 months (range, 1-9). No significant improvement in terms of symptomatic status or analgesic consumption was recorded. The treatment was well tolerated, and no significant local or systemic toxicity was observed. Conclusions: Disodium pamidronate at a dose of 45 mg every 3 weeks is not capable of inducing sclerosis of lytic lesions from pretreated breast cancer. Further trials concentrating on higher dosages of disodium pamidronate are warranted.

Original languageEnglish
Pages (from-to)340-342
Number of pages3
JournalTumori
Volume79
Issue number5
Publication statusPublished - 1993

Fingerprint

pamidronate
Sclerosis
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Bone Diseases
Therapeutics
Analgesics
Hormones
Drug Therapy

Keywords

  • bone metastases
  • breast cancer
  • pamidronate

ASJC Scopus subject areas

  • Cancer Research

Cite this

Disodium pamidronate in the treatment of bone metastases from breast cancer. / Colleoni, M.; Bochicchio, A. M.; Nole, F.; Bajetta, E.

In: Tumori, Vol. 79, No. 5, 1993, p. 340-342.

Research output: Contribution to journalArticle

Colleoni, M, Bochicchio, AM, Nole, F & Bajetta, E 1993, 'Disodium pamidronate in the treatment of bone metastases from breast cancer', Tumori, vol. 79, no. 5, pp. 340-342.
Colleoni, M. ; Bochicchio, A. M. ; Nole, F. ; Bajetta, E. / Disodium pamidronate in the treatment of bone metastases from breast cancer. In: Tumori. 1993 ; Vol. 79, No. 5. pp. 340-342.
@article{ed2de49477954265b723e86339c1fef6,
title = "Disodium pamidronate in the treatment of bone metastases from breast cancer",
abstract = "Aims and Background: Symptomatic relief of bone metastases with biphosphonates has been previously reported, but limited data are available on the possibility of the induction of sclerosis in osteolytic lesions. Methods: We therefore initiated an open study with disodium pamidronate (45 mg infused over 1 h and repeated every 21 days) in patients with bone metastases from breast cancer pretreated with chemotherapy and/or hormone therapy. Fourteen patients with measurable lytic or mixed bone disease entered the study. No other systemic therapy for breast cancer was allowed after their inclusion in the study. Results: No radiologic evidence of bone sclerosis of lytic disease was seen. After 2 months of therapy, 9 patients had progressed and 5 had stable disease. The median time to progression of bone disease was 1.6 months (range, 1-9). No significant improvement in terms of symptomatic status or analgesic consumption was recorded. The treatment was well tolerated, and no significant local or systemic toxicity was observed. Conclusions: Disodium pamidronate at a dose of 45 mg every 3 weeks is not capable of inducing sclerosis of lytic lesions from pretreated breast cancer. Further trials concentrating on higher dosages of disodium pamidronate are warranted.",
keywords = "bone metastases, breast cancer, pamidronate",
author = "M. Colleoni and Bochicchio, {A. M.} and F. Nole and E. Bajetta",
year = "1993",
language = "English",
volume = "79",
pages = "340--342",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Disodium pamidronate in the treatment of bone metastases from breast cancer

AU - Colleoni, M.

AU - Bochicchio, A. M.

AU - Nole, F.

AU - Bajetta, E.

PY - 1993

Y1 - 1993

N2 - Aims and Background: Symptomatic relief of bone metastases with biphosphonates has been previously reported, but limited data are available on the possibility of the induction of sclerosis in osteolytic lesions. Methods: We therefore initiated an open study with disodium pamidronate (45 mg infused over 1 h and repeated every 21 days) in patients with bone metastases from breast cancer pretreated with chemotherapy and/or hormone therapy. Fourteen patients with measurable lytic or mixed bone disease entered the study. No other systemic therapy for breast cancer was allowed after their inclusion in the study. Results: No radiologic evidence of bone sclerosis of lytic disease was seen. After 2 months of therapy, 9 patients had progressed and 5 had stable disease. The median time to progression of bone disease was 1.6 months (range, 1-9). No significant improvement in terms of symptomatic status or analgesic consumption was recorded. The treatment was well tolerated, and no significant local or systemic toxicity was observed. Conclusions: Disodium pamidronate at a dose of 45 mg every 3 weeks is not capable of inducing sclerosis of lytic lesions from pretreated breast cancer. Further trials concentrating on higher dosages of disodium pamidronate are warranted.

AB - Aims and Background: Symptomatic relief of bone metastases with biphosphonates has been previously reported, but limited data are available on the possibility of the induction of sclerosis in osteolytic lesions. Methods: We therefore initiated an open study with disodium pamidronate (45 mg infused over 1 h and repeated every 21 days) in patients with bone metastases from breast cancer pretreated with chemotherapy and/or hormone therapy. Fourteen patients with measurable lytic or mixed bone disease entered the study. No other systemic therapy for breast cancer was allowed after their inclusion in the study. Results: No radiologic evidence of bone sclerosis of lytic disease was seen. After 2 months of therapy, 9 patients had progressed and 5 had stable disease. The median time to progression of bone disease was 1.6 months (range, 1-9). No significant improvement in terms of symptomatic status or analgesic consumption was recorded. The treatment was well tolerated, and no significant local or systemic toxicity was observed. Conclusions: Disodium pamidronate at a dose of 45 mg every 3 weeks is not capable of inducing sclerosis of lytic lesions from pretreated breast cancer. Further trials concentrating on higher dosages of disodium pamidronate are warranted.

KW - bone metastases

KW - breast cancer

KW - pamidronate

UR - http://www.scopus.com/inward/record.url?scp=0027849666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027849666&partnerID=8YFLogxK

M3 - Article

VL - 79

SP - 340

EP - 342

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -